Effect of Triamcinolone Acetonide on Vascular Endothelial Growth Factor and Occludin Levels in Branch Retinal Vein Occlusion

McAllister, Ian L.; Vijayasekaran, Shyan; Chen, Simon; Yu, Dao‐Yi

doi:10.1016/j.ajo.2008.12.006

Cited by 83 publications

(69 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of its anti-inflammatory and anti-VEGF effects, 14 corticosteroids have been reported to reduce ME and improve visual function in ME secondary to BRVO. [15][16][17][18] Intravitreal triamcinolone acetonide (IVTA) has been found to be effective in reducing ME and improving visual function, but its use is limited by high risk of IOP elevation and cataract progression.…”

Section: Introductionmentioning

confidence: 99%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of combination therapy of intravitreal bevacizumab (IVB) with single simultaneous posterior subtenon triamcinolone acetonide (STA) for treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods This was a prospective, randomized, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Reinjections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6-month follow-up period were compared. Results BCVA showed significant improvement in two groups at 6 months. In addition, CMT showed significant decrease in two groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the two groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034).Conclusion Although combination therapy of IVB with a single simultaneous STA for treatment of ME secondary to BRVO did not affect the visual outcomes compared with IVB monotherapy, it had a benefit of reducing the number of additional IVB injections.

show abstract

Section: Introductionmentioning

confidence: 99%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

show abstract

“…The dexamethasone 0.7-mg intravitreal implant (Ozurdex®, Allergan, Irvine, CA, USA) is a sustained-biodegradable implant containing the corticosteroid, dexamethasone. Corticosteroids including dexamethasone are known to have anti-inflammatory and antiangiogenic properties and may inhibit the expression of VEGF and other proinflammatory cytokines such as IL-6, ICAM-1, and MCP-1 (8,22,23) . The choroid is the vascular layer between the retina and the sclera that provides blood supply to the eye and plays an important role in ocular nutrition.…”

Section: Discussionmentioning

confidence: 99%

Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

Arifoğlu

Duru

Altunel

et al. 2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: The objective of this study was to evaluate subfoveal choroidal thickness (SFCT ) using enhanced depth imaging optical coherence tomography (EDI-OCT ) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection. Methods: Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant. Results:The mean SFCT measured in 39 patients with BRVO was 299.41 ± 55.86 μm, significantly greater than that in contralateral eyes (283.76 ± 57.44 μm; p=0.009) and control eyes (276.14 ± 39.06 μm; p=0.044). The mean SFCT after the treatment was 279.64 ± 50.96 μm, significantly thinner than that before intravitreal dexamethasone therapy (p=0.004). Conclusions: SFCT in treatment-naive BRVO eyes was significantly greater than that in contralateral eyes and healthy eyes and decreased significantly after intravitreal dexamethasone implantation.

show abstract

“…In a porcine model of RVO, triamcinolone treatment, a widely used glucocorticoid in ocular applications, reduced VEGF and increased tight junction occludin levels in the retina, suggesting increased BRB integrity (McAllister et al, 2009). A study conducted to examine the impact of Streptococcus suis infection on blood-CSF (cerebral spinal fluid) barrier showed that the glucocorticoid dexamethasone improved the barrier function by preventing tight junction protein reorganization and degradation, and attenuated ERK activation and matrix metalloproteinase 3 (MMP3) expression (Tenenbaum et al, 2008).…”

Section: Mapk Activation and Inflammation In The Retinamentioning

confidence: 99%

“…In a porcine model of RVO, triamcinolone treatment reduced the glial activation marker GFAP expression in Müller cells, and also increased BRB integrity, as evidenced by reduced VEGF and increased tight junction occludin levels, potentially contributing to the resolution of edema in the retina (McAllister et al, 2009). …”

Section: Mapk Pathway and Water Permeability In Response To Oxidativementioning

confidence: 99%

Retinal Vein Occlusion Induced by a MEK Inhibitor - Impact of Oxidative Stress on the Blood-Retinal Barrier

Yang¹,

Huang²

2012

Oxidative Stress and Diseases

View full text Add to dashboard Cite

Effect of Triamcinolone Acetonide on Vascular Endothelial Growth Factor and Occludin Levels in Branch Retinal Vein Occlusion

Cited by 83 publications

References 39 publications

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

Retinal Vein Occlusion Induced by a MEK Inhibitor - Impact of Oxidative Stress on the Blood-Retinal Barrier

Contact Info

Product

Resources

About